Clinical trial · Interventional
ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy
Prospective, Multi-Center Study of the ClariCore™ Optical Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy For Prostate Tissue Classification Algorithm Development
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to collect information on prostate tissue biopsies collected with the ClariCore System during a radical prostatectomy procedure. The ClariCore System is designed to improve how biopsies are taken from the prostate by using light sensors (fiber optics) that can see changes in the tissue. The information collected from the study will be used to develop a method to tell the difference between normal and suspicious tissue to help guide the physician during a biopsy procedure.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ClariCore System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ClariCore System
- description
- Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during the patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
- interventionNames
- Device: ClariCore System
Primary outcomes (1)
- measure
- Optical spectra measurements will be correlated with biopsy tissue core samples in patients with known prostate cancer undergoing radical retropubic prostatectomy surgery to develop a prostate tissue classification database
- timeFrame
- Through study completion which ends at time of procedure completion
Secondary outcomes (1)
- measure
- All adverse events reported during the procedure that are related to the ClariCore System
- timeFrame
- Through study completion which ends at time of procedure completion
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria:
* Patient scheduled for radical retropubic prostatectomy
* Prostate volume \> 20cc and height at least 22mm (at the area(s) to be biopsied) as verified by ultrasound or MRI
* Patient, or authorized representative signs a written Informed Consent form to participate in the study, prior to any study mandated determinations or procedure
Exclusion Criteria:
* Patient opted for robotic (da Vinci robot) or laparoscopic surgery
* Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies)
* Patient has systemic infection or evidence of any surgical site infection (superficial or organ space), including active urinary tract infection
* Bladder cancer (current or prior)
* Actively taking blood thinning agents (with the exception of low dose aspirin {81 mg}, Plavix, Coumadin etc.) or severe medical comorbidity prohibiting halting of anticoagulation therapies or history of bleeding disorder (e.g. coagulopathy)
* Any malignancy other than non-melanoma cell skin cancer, unless no evidence of disease for a minimum of 5 years
* Hormone therapy for locally advanced disease (except patients on 5-alpha reductase inhibitors to reduce the size of the prostate)
* Neo-adjuvant hormonal therapy
* Salvage radical prostatectomy, i.e., patients having surgery due to failure of previous therapy (radiation, brachytherapy, cryotherapy, etc.)
* Patient has compromised immune system or autoimmune disease (WBC \< 4000 or \> 20,000)
* Patient is not likely to comply with the follow-up evaluation schedule
* Patient is participating in a clinical trial of another investigational drug or device
* Patient is mentally incompetent or a prisonerReferences
Publications (0)
Data not yet available